Studies of coordinated compounds containing ruthenium (Ru
2+ and Ru
3+) have shown very effective
in vitro results for the treatment of cancer and neglected diseases such as leishmaniasis. In this paper, we present the synthesis of the compound [Ru(Cl)
3(H
2O)
2(gly)], which was characterized by spectroscopic (Ultraviolet-visibleand infrared) and thermal analysis (Thermogravimetry/Derived Thermogravimetry and Thermogravimetry/Differential Thermal Analysis). The analysis of the compound in the Ultraviolet-visibleregion showed a 290 nm band
λmax (
ε= 1.685 × 10
3 L
·cm
-1·mol
-1), attributed to the ligand metal charge transfer (LMCT). The spectroscopy (IR) showed major vibrational bands at δ
a (-COO
-) 1664 cm
-1, δ
s (-COO
-) 1388 cm
-1, δ
s (
) 1571 cm
-1 and δ
s (CCN) 889 cm
-1. The thermal analysis by TG/DTG and TG-DTA indicated that the complex has five consecutive stages of decomposition: at 115
°C (TG = 12.18%; Calculated = 11.32%) H
2O (coordinating water), exothermic peaks at 230
°C, 307
°C, 440
°C and 463
°C due to oxidative decomposition of glycine, followed by the formation of RuClO residue at 665
°C (TG = 41.11%; Calculated = 40.81%). The thermal characterization suggested the stoichiometry of the complex [RuCl
3(H
2O)
2(gly)]. The antileishmanial capacity of this compound was also evaluated and the results indicated a 31% decrease in the parasitic infection of macrophages and a 1.5 to 3 fold reduction in the number of parasites per cell after treatment with 100 μg/mL of the complex. These results support the possible use of this compound as a therapeutic alternative against medical and veterinary parasites.